Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can special lenses put the brakes on childhood myopia?

NCT ID NCT05840185

Disease control Sponsor: Essilor International Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial tests whether a new type of spectacle lens can slow the progression of myopia (nearsightedness) in children aged 8 to 13. Over 12 months, researchers measure changes in eye length and prescription, comparing results to a historical group that wore standard lenses. The goal is to find a simple, everyday solution to reduce worsening eyesight in kids.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
special myopia control spectacle lenses (DAL) worn for 12 months
What this could lead to
If effective, these lenses could offer a simple, non-invasive way to slow worsening nearsightedness in children, reducing the risk of severe eye problems later in life.
What could go wrong
This is a small, early study with only 40 children and no control group—results are compared to a historical group from another trial, which may not be reliable. The lenses may not slow myopia significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

41 people

The number who actually took part.

Started

Aug 2023

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 13 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Volunteer subject and guardian, fluent English spoken, willing to follow protocol and able to read, comprehend and sign the informed consent \& assent form. * 8 to 13 years old at time of informed consent and assent. * Spherical equivalent refractive error (SER) by manifest refraction between -0.75 and -4.75 D in each eye. * Astigmatism, if present, of not more than 1.50 D. * Difference in SER between the two eyes (Anisometropia) by manifest refraction not more than 1.00 D. * Best corrected visual acuity in each eye equal to or better than +0.10 logMAR (≥ 20/25 as Snellen) * Be in good general health based on his/her and parent's/guardian's knowledge. Absence of ocular disease with full ophthalmic examination. Without any ocular or systemic condition known to affect refractive status. * Absence of strabismus by cover test at near or distance wearing correction. * Absence of amblyopia * Without ocular or systemic medications which, in the investigator's opinion, may significantly affect pupil size, accommodation or refractive state. Exclusion Criteria: * Vulnerability of subject * History of myopia control intervention * Participation in any clinical study within 30 days of the Baseline visit.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eye disorder myopia refractive error

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myopia

Contacts and locations

Locations

  • Essilor R&D Centre Singapore

    Singapore, 339346, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.